GeneDx Holdings Corp. (NASDAQ:WGS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of GeneDx Holdings Corp. (NASDAQ:WGS) have been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $38.00.

Several analysts recently issued reports on WGS shares. Wells Fargo & Company started coverage on GeneDx in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $34.00 price target for the company. Jefferies Financial Group started coverage on GeneDx in a report on Monday, June 3rd. They issued a “hold” rating and a $21.00 price target for the company. BTIG Research boosted their target price on shares of GeneDx from $35.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Craig Hallum lifted their price target on shares of GeneDx from $43.00 to $46.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Finally, The Goldman Sachs Group upped their price objective on shares of GeneDx from $28.00 to $32.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st.

GeneDx Trading Down 0.6 %

WGS stock opened at $40.40 on Friday. GeneDx has a 52 week low of $1.16 and a 52 week high of $43.32. The company has a market cap of $1.06 billion, a price-to-earnings ratio of -7.80 and a beta of 2.29. The company has a quick ratio of 2.22, a current ratio of 2.38 and a debt-to-equity ratio of 0.27. The business has a fifty day simple moving average of $33.49 and a 200-day simple moving average of $23.38.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Tuesday, July 30th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.15. The company had revenue of $70.51 million for the quarter, compared to the consensus estimate of $58.90 million. GeneDx had a negative return on equity of 22.71% and a negative net margin of 48.21%. On average, equities research analysts expect that GeneDx will post -0.75 EPS for the current year.

Insider Transactions at GeneDx

In other news, CEO Katherine Stueland sold 3,639 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $33.33, for a total transaction of $121,287.87. Following the transaction, the chief executive officer now owns 95,457 shares of the company’s stock, valued at $3,181,581.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Katherine Stueland sold 3,639 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $33.33, for a total transaction of $121,287.87. Following the sale, the chief executive officer now directly owns 95,457 shares of the company’s stock, valued at approximately $3,181,581.81. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Kevin Feeley sold 895 shares of GeneDx stock in a transaction on Monday, September 9th. The stock was sold at an average price of $33.33, for a total transaction of $29,830.35. Following the completion of the transaction, the chief financial officer now directly owns 39,910 shares of the company’s stock, valued at approximately $1,330,200.30. The disclosure for this sale can be found here. In the last 90 days, insiders sold 743,868 shares of company stock valued at $24,114,996. Insiders own 28.10% of the company’s stock.

Hedge Funds Weigh In On GeneDx

A number of large investors have recently bought and sold shares of the business. Acadian Asset Management LLC bought a new stake in GeneDx in the second quarter valued at $34,000. nVerses Capital LLC acquired a new position in GeneDx during the 2nd quarter valued at about $50,000. Thompson Davis & CO. Inc. grew its position in GeneDx by 20.8% in the 1st quarter. Thompson Davis & CO. Inc. now owns 24,094 shares of the company’s stock worth $220,000 after purchasing an additional 4,150 shares during the last quarter. Decheng Capital LLC acquired a new stake in shares of GeneDx in the fourth quarter valued at approximately $285,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of GeneDx during the second quarter valued at approximately $290,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.